Status:
public
Videos: (
0
) Documents: (
0
) Comments: (
0
)
Group description
Group Videos
No videos have been added jet. You may join this group and add yours now.
Group Documents
No documents have been added jet. You may join this group and add yours now.
News
- Human monoclonal antibody firm collaborating with Big Pharma
Immunome, which has developed a way to clone monoclonal human antibodies that can be used to help develop more effective cancer drugs and with potential applications for rare diseases, has signed its first research and development partnership with a Big Pharma company. The Wynnewood, Pennsylvania company’s approach differs from its competitors, says Timothy Pelura, the CEO. [...] - Peregrine to Present at BIO CEO and Investor Conference on Tuesday, February 14, 2012 at 8:30 AM EST
TUSTIN, CA-- - Peregrine Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and infectious diseases, today announced ... - Biogen to acquire developer of fibrosis treatment
(Reuters) - Biogen Idec Inc said on Tuesday it has agreed to acquire Stromedix Inc, a privately held company developing treatments for fibrosis and organ failure, for $75 million in cash -- and potential additional payments of up to $487.5 million. Stromedix's most advanced candidate, STX-100, is a monoclonal antibody that has shown promise in early stage trials to treat fibrosis, an ... - IMMUNE Pharmaceuticals Granted US$1 Million (NIS 3.8M) by the Office of the Chief Scientist in Israel
HERZLIYA, Israel and NEW YORK -- IMMUNE Pharmaceuticals, an emerging leader in the development of monoclonal antibody based therapeutics for the treatment of inflammatory diseases and cancer, today announced ... - Compugen Cancer Target Results Demonstrate Significant Potential for Cancer Immunotherapy
Compugen Ltd. announced today results demonstrating the therapeutic potential of CGEN-15001T as a drug target for treatment of multiple cancers by means of monoclonal antibody therapy. - Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016
NEW YORK, Feb. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Indian Diagnostic & Therapeutic Antibodies Market Report & Forecast: 2011-2016 ... - Biogen Idec to Acquire Stromedix
Biogen Idec and Stromedix, Inc. today announced that they have entered into a definitive agreement under which Biogen Idec will acquire Stromedix Inc., a privately held biotechnology company focused on innovative therapies for fibrosis and organ failure. - Seattle Genetics Inc. Earnings: Beats Analysts’ Estimates as Loss Narrows
Here's a closer look at the company's latest earnings release... - Immunomedics Awarded Broad Patent for Anti-CD20 and Anti-CD22 Combination Therapy
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ... - Immunomedics Announces Second Quarter Fiscal 2012 Results and Clinical Program Developments
MORRIS PLAINS, N.J. -- Immunomedics, Inc. , a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other ...